尼洛替尼(Nilotinib Hydrochloride) - 药物靶点：Bcr-Abl x CSF-1R x DDR1 x PDGFR x c-Kit_在研适应症：加速期慢性骨髄性白血病，费城染色体阳性白血病，加速期费城染色体阳性慢性粒细胞白血病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Nilotinib、Nilotinib Hydrochloride Hydrate、Nilotinib hydrochloride hydrate (JAN)

+ [14]

靶点

Bcr-Abl x CSF-1R x DDR1 x PDGFR x c-Kit

作用机制

Bcr-Abl抑制剂(bcr-abl酪氨酸激酶抑制剂)、CSF-1R拮抗剂(集落刺激因子1受体拮抗剂)、DDR1拮抗剂(盘状结构域受体-1拮抗剂)

治疗领域

肿瘤血液及淋巴系统疾病消化系统疾病+ [3]

在研适应症

加速期慢性骨髄性白血病费城染色体阳性白血病加速期费城染色体阳性慢性粒细胞白血病+ [7]

非在研适应症

听神经瘤肢端雀斑恶性黑色素瘤急性淋巴细胞白血病+ [24]

原研机构

Novartis Pharma AG

在研机构

Novartis Pharmaceuticals Corp.Novartis Europharm Ltd.

Xspray Pharma AB

+ [6]

非在研机构

北京诺华制药有限公司Novartis Pharma Stein AGNovartis Pharma AG

最高研发阶段批准上市

首次获批日期

瑞士 (2007-07-24),

费城染色体阳性慢性粒细胞白血病

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (日本)、孤儿药 (美国)

登录后查看时间轴

结构

分子式C28H25ClF3N7O2

InChIKeyYCBPQSYLYYBPDW-UHFFFAOYSA-N

CAS号923288-90-8

关联

239

项与尼洛替尼相关的临床试验

IRCT20200623047902N17 / Suspended

Bioequivalence study of Nilotinib 200mg capsule manufactured by Rooyan darou versus Tasigna 200 mg in healthy volunteers in the fasted condition

开始日期2024-10-22

申办/合作机构-

NCT06409936 / Not yet recruiting临床2期IIT

Asciminib as Single Agent or in Combination With Nilotinib in the 1st-line Treatment of BCR-ABL1+ Chronic Myeloid Leukemia: a Randomized GIMEMA-GELMC Phase II Study PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

A phase 2, interventional, randomized unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in combination with nilotinib 300 mg BID (arm B).
All patients in both arm A and arm B will be treated for a minimum of 2 years (core phase). If they will have achieved a DMR (MR4), or if it will be in the interest of the patient, the treatment will be continued.
During the consolidation phase (2 years) asciminib will be continued at the same dose in both arms; in the combination arm the nilotinib dose will be reduced to 300 mg daily.
The patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment (TFR phase). The rate of TFR at 5 year (1 year after discontinuation) will be evaluated.

开始日期2024-09-01

申办/合作机构

Gruppo Italiano Malattie EMatologiche dell'Adulto

CTIS2024-514448-10-00 / Not yet recruiting

- BLCL-NIL-FDA-02

开始日期2024-08-09

申办/合作机构

Bluepharma Indústria Farmacêutica SA

100 项与尼洛替尼相关的临床结果

登录后查看更多信息

100 项与尼洛替尼相关的转化医学

登录后查看更多信息

100 项与尼洛替尼相关的专利（医药）

登录后查看更多信息

2,558

项与尼洛替尼相关的文献（医药）

2024-12-01·MOLECULAR BIOLOGY REPORTS

Investigating the impact of SMAD2 and SMAD4 downregulation in colorectal cancer and their correlation with immune markers, prognosis, and drug resistance and sensitivity

Article

作者: Peymani, Maryam ; Amani, Melika Saadat

BACKGROUND:

While many genes linked to colorectal cancer (CRC) contribute to cancer development, a thorough investigation is needed to explore crucial hub genes yet to be fully studied. A pivotal pathway in CRC is transforming growth factor-beta (TGF-β). This study aimed to assess SMAD2 and SMAD4 gene expression from this pathway.

METHODS AND RESULTS:

Counted data from the Cancer Genome Atlas (TCGA) were examined, comparing 483 tumor and 41 normal samples. Using clinical data, genes impacting overall survival (OS) were evaluated. GSE39582 was employed to confirmed the levels of genes in CRC compared to the normal samples. Additionally, employing unhealthy samples and the RT-qPCR means our outcomes was validated. Finally, PharmacoGx information were utilized to connect the levels of potential genes to drug tolerance and susceptibility. Our findings showed SMAD2 and SMAD4 levels in TGF-β signaling were more significant than other pathway genes. Our findings indicated that the protein levels of these genes were lower in malignant tissues than in healthy tissues. Results revealed a significant correlation between low levels of SMAD2 and unfavorable OS in CRC individuals. RT-qPCR results demonstrated decreased expressions of both SMAD2 and SMAD4 in cancer tissues compared to elevated levels in adjacent normal samples. Our results showed significant association between selected genes and immune cell infiltration markers such as CD8+, and B-cells. Our results indicated a potential association among the levels of SMAD2 and SMAD4 genes and tolerance and susceptibility to Nilotinib and Panobinostat drugs.

CONCLUSION:

Reduced expression of SMAD2 and SMAD4 may be pivotal in CRC progression, impacting downstream genes unrelated to patient OS. These findings suggest a potential role for SMAD2 and SMAD4 as predictive markers for drug response in CRC patients.

2024-12-01·Current computer-aided drug design

Identification of Prognostic Markers and Potential Therapeutic Targets using Gene Expression Profiling and Simulation Studies in Pancreatic Cancer

Article

作者: Singh, Samvedna ; Jhinjharia, Divya ; Gupta, Himanshi ; Sahi, Shakti ; Kaushik, Aman Chandra

Background::

Pancreatic ductal adenocarcinoma (PDAC) has a 5-year relative survival rate of less than 10% making it one of the most fatal cancers. A lack of early measures of prognosis, challenges in molecular targeted therapy, ineffective adjuvant chemotherapy, and strong resistance to chemotherapy cumulatively make pancreatic cancer challenging to manage

Objective::

The present study aims to enhance understanding of the disease mechanism and its progression by identifying prognostic biomarkers, potential drug targets, and candidate drugs that can be used for therapy in pancreatic cancer.

Methods::

Gene expression profiles from the GEO database were analyzed to identify reliable prognostic markers and potential drug targets. The disease's molecular mechanism and biological pathways were studied by investigating gene ontologies, KEGG pathways, and survival analysis to understand the strong prognostic power of key DEGs. FDA-approved anti-cancer drugs were screened through cell line databases, and docking studies were performed to identify drugs with high affinity for ARNTL2 and PIK3C2A. Molecular dynamic simulations of drug targets ARNTL2 and PIK3C2A in their native state and complex with nilotinib were carried out for 100 ns to validate their therapeutic potential in PDAC.

Results::

Differentially expressed genes that are crucial regulators, including SUN1, PSMG3, PIK3C2A, SCRN1, and TRIAP1, were identified. Nilotinib as a candidate drug was screened using sensitivity analysis on CCLE and GDSC pancreatic cancer cell lines. Molecular dynamics simulations revealed the underlying mechanism of the binding of nilotinib with ARNTL2 and PIK3C2A and the dynamic perturbations. It validated nilotinib as a promising drug for pancreatic cancer.

Conclusion::

This study accounts for prognostic markers, drug targets, and repurposed anti-cancer drugs to highlight their usefulness for translational research on developing novel therapies. Our results revealed potential and prospective clinical applications in drug targets ARNTL2, EGFR, and PI3KC2A for pancreatic cancer therapy.

2024-11-07·BLOOD

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Article

作者: Grove, Carolyn ; Shortt, Jake ; Grigg, Andrew P. ; Reynolds, John ; Walia, Mannu ; Branford, Susan ; Filshie, Robin ; Forsyth, Cecily ; Harrup, Rosemary ; Shanmuganathan, Naranie ; Hughes, Timothy P. ; Yeung, David T. ; Ross, David M. ; Cunningham, Ilona ; Viiala, Nicholas ; Yong, Agnes S. M. ; Lane, Steven ; Wright, Matthew ; Browett, Peter ; Chee, Lynette ; D’Souza, Alwyn

Abstract:

Asciminib is a myristoyl site BCR::ABL1 inhibitor approved for patients with chronic-phase chronic myeloid leukemia (CP-CML) failing ≥2 prior lines of therapy. The Australasian Leukaemia and Lymphoma Group conducted the Asciminib Evaluation in Newly Diagnosed CML study to assess efficacy of asciminib for newly diagnosed CP-CML. Patients commenced asciminib 40 mg twice daily. Patients with treatment failure, defined as BCR::ABL1 of >10% at 3 or 6 months, or >1% at 12 or 18 months, received either imatinib, nilotinib, or dasatinib in addition to asciminib. In patients with suboptimal response, defined as levels of 1% to 10% at 6 months, >0.1% to 1% at 12 months, or >0.01% to 1% at 18 months, the asciminib dose was increased to 80 mg twice daily. With a median follow-up of 21 months (range, 0-36), 82 of 101 patients continue asciminib. Most common reasons for treatment discontinuation were adverse events (6%), loss of response (4%), and withdrawn consent (5%). There were no deaths; 1 patient developed lymphoid blast crisis. The coprimary end points were early molecular response (BCR::ABL1 of ≤10% at 3 months), achieved in 93% (96% confidence interval [CI], 86-97%), and major molecular response by 12 months achieved in 79%; (95% CI, 70-87%), respectively. Cumulative incidence of molecular response 4.5 was 53% by 24 months. One patient had 2 cerebrovascular events; no other arterial occlusive events were reported. Asciminib as frontline CP-CML therapy leads to high rates of molecular response with excellent tolerance and a low rate of discontinuation for toxicity. This trial was registered at https://www.anzctr.org.au/ as #ACTRN12620000851965.

164

项与尼洛替尼相关的新闻（医药）

2024-11-19

·医药地理

FDA批准白血病靶向药nilotinib新剂型 | 一图读懂：2024年11月上半月全球新药研发进展

2024年版第21期《全球药研新动态》新鲜出炉！全球新药批准概况 2024年11月上半月，美国食品药品监督管理局（FDA）批准新药申请（NDA）2个。数据来源：Pharma ONE药物研发大数据平台，中国医药工业信息中心全球药品研发概况 2024年11月上半月，全球进入注册前阶段的新药有1个。全球进入III期临床试验阶段的新药有5个，其中包括2个新化学实体药物（NCEs）。数据来源：Pharma ONE药物研发大数据平台，中国医药工业信息中心中国药品注册申报概况 2024年11月上半月，国家药品监督管理局药品审评中心（CDE）共受理新注册申请829件（按受理号计，一次性进口申请除外），具体情况如下图。统计申报临床的药品数量，CDE新受理临床申请165件（按受理号计），其中国产药144件、进口药21件。统计申请上市的药品数量，CDE新受理生产/上市注册申请共265件（按受理号计），其中国产药250件，进口药15件。数据来源：Pharma ONE药物研发大数据平台，中国医药工业信息中心中国药品批准概况 2024年11月上半月，国家药品监督管理局（NMPA）共批准药品上市申请123件。其中，国产药品93件，进口药品30件。国产药涉及59个品种，其中包括58个化药，1个中药。进口药品涉及16个品种，其中包括14个化药，2个生物制品。数据来源：Pharma ONE药物研发大数据平台，中国医药工业信息中心扫码免费下载完整报告 END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

临床3期申请上市

2024-11-16

·药明康德

可抗32种耐药突变，FDA批准抗癌小分子疗法

▎药明康德内容团队编辑 Azurity Pharmaceuticals日前宣布，美国FDA已批准Danziten（nilotinib）用于治疗新确诊的费城染色体阳性慢性髓系白血病（Ph+ CML）慢性期（CP）成年患者，以及对包括伊马替尼（imatinib）在内的既往疗法有耐药或不耐受的慢性期和急性期（AP）成年患者。根据新闻稿，这是FDA批准的首个无需用餐限制的nilotinib药物。 Nilotinib是一款BCR-ABL激酶抑制剂，该药物能与ABL蛋白激酶域的非活性构象结合并稳定其构象。体外实验中，nilotinib可抑制BCR-ABL介导的小鼠白血病细胞系和Ph+ CML患者衍生的人类细胞系的增殖。在测试的33种BCR-ABL激酶突变中，nilotinib对32种伊马替尼耐药性突变仍具有活性。过去试验显示，nilotinib对新确诊的Ph+CML-CP和耐药性或不耐受Ph+CML-CP和CML-AP成人有效。然而，在此之前的获批疗法的生物利用度不稳定，尤其是在与食物一起服用时更为显著。分析显示，在与食物一起不当服用时，过往获批的nilotinib会以浓度依赖性方式，显著延长体表心电图（ECG）上的QT间期。因此，服用该疗法期间时严格禁食对于避免心脏毒性至关重要。 Danziten是nilotinib的重新设计的配方，不受进餐时间限制，并与以往获批疗法具有相似的疗效，但生物利用度更高，可以更低的剂量来服用。Danziten表现出一致的药代动力学，无论患者空腹状态或进餐类型如何，Danziten暴露量均无临床显著差异。Danziten由于取消了禁食要求，有潜力改善患者的治疗依从性。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS. Retrieved November 15, 2024 from https://azurity.com/azurity-pharmaceuticals-inc-announces-fda-approval-of-danziten-nilotinib-tablets-the-first-and-only-nilotinib-with-no-mealtime-restrictions/ [2] Danziten Prescribing Information. Retrieved November 15, 2024 from https://azurity.com/wp-content/uploads/2024/11/Danziten-Prescribing-Information.pdf 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

申请上市

2024-11-15

·Pharmaceutical Technology

FDA approves Azurity Pharmaceuticals’ Danziten for CML treatment

Danziten is set to be available soon via Biologics by McKesson and Limited Specialty Distribution. Credit: Motortion Films via Shutterstock. The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only nilotinib formulation that does not require mealtime restrictions, to treat chronic myeloid leukaemia (CML). It is indicated for adults with newly diagnosed Philadelphia chromosome-positive (Ph+) CML in the chronic phase, as well as those who are resistant or intolerant to previous therapies that included imatinib. Danziten’s reengineered formulation is said to provide equivalent efficacy to Tasigna but with enhanced bioavailability, enabling a lower dosage. Its approval is expected to enhance patient adherence to treatment, as it eliminates the need for fasting, which has been a challenge with current therapies. While Tasigna, the existing nilotinib treatment, has proven efficacy for Ph+ CML in chronic and acute phases, its bioavailability is affected by food intake, necessitating strict fasting to prevent cardiotoxicity. An optimal tyrosine kinase inhibitor therapy may lead to deep molecular responses, and for some patients, even treatment-free remission, the company noted. Azurity Pharmaceuticals CEO Richard Blackburn said: “Danziten offers a new nilotinib treatment option with the equivalent efficacy to Tasigna, but without the fasting requirements of Tasigna. “Unlike Tasigna, the boxed warning on the Danziten label has no requirement for patients to take their medication in a fasted state, liberating CML patients from mealtime restrictions.” Danziten is set to be shortly available via Biologics by McKesson and Limited Specialty Distribution. In September this year, the FDA approved the company’s Nymalize , an oral solution provided in a 5ml prefilled ENFit syringe as an alternative for adult subarachnoid haemorrhage patients. In 2022, it received approval for Konvomep, a treatment for active benign gastric ulcers and risk reduction of upper gastrointestinal bleeding in critically ill patients.

上市批准

100 项与尼洛替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06413	尼洛替尼	L01XE08	DB04868

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
加速期慢性骨髄性白血病	美国	Novartis Pharmaceuticals Corp.	2014-01-22
费城染色体阳性白血病	欧盟	Novartis Europharm Ltd.	2007-11-19
费城染色体阳性白血病	冰岛	Novartis Europharm Ltd.	2007-11-19
费城染色体阳性白血病	列支敦士登	Novartis Europharm Ltd.	2007-11-19
费城染色体阳性白血病	挪威	Novartis Europharm Ltd.	2007-11-19
加速期费城染色体阳性慢性粒细胞白血病	美国	Novartis Pharmaceuticals Corp.	2007-10-29
慢性期费城染色体阳性慢性粒细胞白血病	美国	Novartis Pharmaceuticals Corp.	2007-10-29
费城染色体阳性慢性粒细胞白血病	瑞士	Novartis Pharma Schweiz AG	2007-07-24

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性期慢性髓性白血病	申请上市	欧盟	Novartis Europharm Ltd.	2024-06-27
转移性胃肠道间质瘤	临床3期	美国	Novartis Pharmaceuticals Corp.	2009-03-01
转移性胃肠道间质瘤	临床3期	中国	Novartis Pharmaceuticals Corp.	2009-03-01
转移性胃肠道间质瘤	临床3期	日本	Novartis Pharmaceuticals Corp.	2009-03-01
转移性胃肠道间质瘤	临床3期	阿根廷	Novartis Pharmaceuticals Corp.	2009-03-01
转移性胃肠道间质瘤	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2009-03-01
转移性胃肠道间质瘤	临床3期	巴西	Novartis Pharmaceuticals Corp.	2009-03-01
转移性胃肠道间质瘤	临床3期	保加利亚	Novartis Pharmaceuticals Corp.	2009-03-01
转移性胃肠道间质瘤	临床3期	加拿大	Novartis Pharmaceuticals Corp.	2009-03-01
转移性胃肠道间质瘤	临床3期	哥伦比亚	Novartis Pharmaceuticals Corp.	2009-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2024	N/A	费城染色体阳性慢性粒细胞白血病	-	Nilotinib	齋窪顧艱築願窪壓獵鏇(廠夢蓋鏇壓淵範繭艱窪) = increased creatinine and thyroid disease in flumatinib group 獵窪繭獵積鏇築鹽選醖 (鑰鹹餘衊廠蓋積獵繭餘 ) 更多	-	2024-12-09
				Dasatinib
ASH2024	N/A	费城染色体阳性慢性粒细胞白血病	-	Imatinib	壓簾窪選鬱窪鹹齋獵顧(廠膚壓齋繭觸顧鏇壓構): HR = 3.11 (95% CI, 1.25 ~ 7.77), P-Value = 0.015	-	2024-12-09
				Nilotinib
NCT01784068 (ENESTfreedom, FDA_CDER) 人工标引	临床2期	慢性期费城染色体阳性慢性粒细胞白血病一线	190	Nilotinib	(襯蓋窪廠夢遞製衊膚遞) = 窪蓋餘鑰襯積夢淵範簾簾鏇憲網窪簾網鹽鏇襯 (選壓壓艱鏇夢餘衊淵膚, 54.8 ~ 69.0) 更多	积极	2024-11-07
				Nilotinib (Loss of MMR)	(襯蓋窪廠夢遞製衊膚遞) = 觸鬱淵顧醖糧齋簾膚獵簾鏇憲網窪簾網鹽鏇襯 (選壓壓艱鏇夢餘衊淵膚 ) 更多
NCT01698905 (ENESTop, FDA_CDER) 人工标引	临床2期	慢性期费城染色体阳性慢性粒细胞白血病	126	Nilotinib (without loss of MMR or confirmed loss of MR4)	鹽鹽製簾鑰糧艱觸範糧(壓夢鬱夢鹹構齋壓觸淵) = 顧範淵壓顧網蓋淵憲醖鑰夢選積淵襯淵蓋廠膚 (壓範齋窪艱餘鑰網構繭, 51.2 ~ 68.9) 更多	积极	2024-11-07
				Nilotinib (Loss of MMR or confirmed loss of MR4)	鹽鹽製簾鑰糧艱觸範糧(壓夢鬱夢鹹構齋壓觸淵) = 蓋鬱網醖顧醖窪繭範繭鑰夢選積淵襯淵蓋廠膚 (壓範齋窪艱餘鑰網構繭 ) 更多
NCT00109707 (CAMN107A2101, FDA_CDER) 人工标引	临床1/2期	慢性期费城染色体阳性慢性粒细胞白血病 \| 加速期费城染色体阳性慢性粒细胞白血病	458	Nilotinib (Ph+ CML-CP)	製範蓋憲醖選鹽鑰遞製(襯範憲壓艱夢齋壓鏇壓) = 糧鹽餘醖積膚觸淵衊選鬱範範鏇齋遞觸醖醖簾 (艱窪願構壓鏇獵繭糧鹹, 46 ~ 57) 更多	积极	2024-11-07
				Nilotinib (Ph+ CML-AP)	鬱餘鏇齋鏇衊襯製膚網(築願鬱齋構鏇鹹壓夢蓋) = 餘鏇簾鹽選簾蓋鬱製築夢顧壓遞網鏇觸襯鏇構 (淵簾積鏇選築鏇鏇夢鹹, 31 ~ 48) 更多
NCT00471497 (ENESTnd, FDA_CDER) 人工标引	临床3期	慢性期费城染色体阳性慢性粒细胞白血病一线	-	Nilotinib 300 mg Twice Daily	顧顧構蓋遞築齋鬱獵鏇(範觸築餘鬱繭夢餘鬱齋) = 獵獵簾願憲簾壓願襯淵獵觸襯製築齋廠憲網構 (襯顧鹹構獵鹹夢積顧憲, 38.4 ~ 50.3) 更多	积极	2024-11-07
				Imatinib 400 mg Once Daily	顧顧構蓋遞築齋鬱獵鏇(範觸築餘鬱繭夢餘鬱齋) = 蓋膚鬱範鹽糧憲膚艱鏇獵觸襯製築齋廠憲網構 (襯顧鹹構獵鹹夢積顧憲, 17.6 ~ 27.6) 更多
ESC2024	N/A	费城染色体阳性慢性粒细胞白血病	-	Nilotinib	顧觸衊構壓製獵遞網範(願齋夢選廠網淵窪蓋憲) = 衊鏇製遞製蓋遞鬱齋壓積餘蓋遞壓膚顧衊襯積 (衊廠醖襯夢鬱壓範構醖, 15.7 ~ 26.2) 更多	-	2024-08-30
NCT01863745 (CTgov)	临床2期	胃肠道间质瘤	15	nilotinib	齋襯獵鹹製鹽鏇襯餘積(選繭廠獵夢蓋醖製壓網) = 築遞糧壓顧醖選範鑰遞襯鬱壓壓觸襯願餘鬱蓋 (壓齋積淵遞選蓋鑰鬱願, 襯襯憲範鑰蓋糧鏇選壓 ~ 繭憲築鬱鹽繭窪鏇觸顧) 更多	-	2024-08-19
NCT02611492 (GRAAPH-2014, Pubmed) 人工标引	临床3期	费城染色体阳性急性淋巴细胞白血病巩固 ABL1	155	Nilotinib + Cytarabine	襯遞積齋夢糧繭簾網衊(衊構鹹鑰鏇獵範窪繭鏇) = 積鏇觸獵壓醖憲廠繭鑰製遞築鬱淵鬱網鹹衊衊 (蓋選廠鏇衊獵廠觸繭鬱 ) 更多	积极	2024-06-06
				Nilotinib	襯遞積齋夢糧繭簾網衊(衊構鹹鑰鏇獵範窪繭鏇) = 廠範遞廠顧獵艱鹹鑰積製遞築鬱淵鬱網鹹衊衊 (蓋選廠鏇衊獵廠觸繭鬱 ) 更多
NCT02602314 (SUSTRENIM, EHA2024) 人工标引	临床4期	费城染色体阳性慢性粒细胞白血病	314	Nilotinib	憲積鹹積願範願衊構淵(蓋醖壓顧製選夢築襯衊) = 範鏇鏇鏇簾鬱鏇願願繭鬱壓簾艱餘淵築憲艱窪 (築窪鏇醖淵壓觸憲艱憲 ) 更多	积极	2024-05-14
				Imatinib	憲積鹹積願範願衊構淵(蓋醖壓顧製選夢築襯衊) = 憲簾憲餘築繭網遞鑰網鬱壓簾艱餘淵築憲艱窪 (築窪鏇醖淵壓觸憲艱憲 ) 更多